[Stroke and phenylpropanolamine: what risk factors and what recommendations in request?].
Die-Kacou
H
H
Département de Pharmacologie clinique, UFR des Sciences Médicales, Université de Cocody, Abidjan, Côte d'Ivoire.
Kamagaté
M
M
Daubrey-Potey
T H
TH
Bamba-Kamagaté
D
D
Yavo
J-C
JC
Balayssac
E
E
Gboignon
V M
VM
Kakou
K A
KA
Gilbernaire
A F
AF
D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage / Q000009:adverse effects*; D000328:Adult; D001067:Appetite Depressants / Q000008:administration & dosage / Q000009:adverse effects*; D016022:Case-Control Studies; D007560:Cote d'Ivoire; D005260:Female; D006801:Humans; D014663:Nasal Decongestants / Q000008:administration & dosage / Q000009:adverse effects*; D010665:Phenylpropanolamine / Q000008:administration & dosage / Q000009:adverse effects*; D011358:Product Surveillance, Postmarketing; D012189:Retrospective Studies; D012307:Risk Factors; D012737:Sex Factors; D020521:Stroke / Q000139:chemically induced*; D013997:Time Factors
D000316:Adrenergic alpha-Agonists; D001067:Appetite Depressants; D014663:Nasal Decongestants; D010665:Phenylpropanolamine